These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19439919)

  • 1. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
    Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH
    Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
    Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
    Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases.
    Dammak A; Zribi J; Boudaya S; Mseddi M; Meziou TJ; Masmoudi A; Ellouze Z; Keskes H; Turki H
    Int J Dermatol; 2009 Jun; 48(6):588-91. PubMed ID: 19538366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 13-year-old girl with recessive dystrophic epidermolysis bullosa presenting with squamous cell carcinoma.
    Ayman T; Yerebakan O; Ciftçioglu MA; Alpsoy E
    Pediatr Dermatol; 2002; 19(5):436-8. PubMed ID: 12383103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
    Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
    Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
    Mallipeddi R; Wessagowit V; South AP; Robson AM; Orchard GE; Eady RA; McGrath JA
    J Invest Dermatol; 2004 May; 122(5):1302-9. PubMed ID: 15140235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
    Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
    Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
    Kivisaari AK; Kallajoki M; Mirtti T; McGrath JA; Bauer JW; Weber F; Königová R; Sawamura D; Sato-Matsumura KC; Shimizu H; Csikós M; Sinemus K; Beckert W; Kähäri VM
    Br J Dermatol; 2008 Apr; 158(4):778-85. PubMed ID: 18284387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of skin cancers in epidermolysis bullosa.
    Venugopal SS; Murrell DF
    Dermatol Clin; 2010 Apr; 28(2):283-7, ix-x. PubMed ID: 20447493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of cutaneous pinch grafts in the healing of patients with dystrophic epidermolysis bullosa wounds: report of four cases].
    Claude O; Binder JP; Bustamante K; Blanchet-Bardon C; Andrivon F; Revol M; Servant JM
    Ann Chir Plast Esthet; 2005 Jun; 50(3):189-96. PubMed ID: 15963838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand.
    Kim M; Li M; Intong-Wheeler LRA; Tran K; Marucci D; Murrell DF
    Acta Derm Venereol; 2018 Jan; 98(1):70-76. PubMed ID: 28853495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa.
    Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D
    J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited epidermolysis bullosa dystrophica and squamous cell carcinoma- A case report.
    Gayathri E; Anbukkarasi K; Lilly SM
    Indian J Pathol Microbiol; 2023; 66(2):360-362. PubMed ID: 37077084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.
    Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J
    Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.
    Kivisaari AK; Kallajoki M; Ala-aho R; McGrath JA; Bauer JW; Königová R; Medvecz M; Beckert W; Grénman R; Kähäri VM
    Br J Dermatol; 2010 Oct; 163(4):726-35. PubMed ID: 20586780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
    Kim M; Murrell DF
    Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
    Bartolo J; Farricha V; Carvalhal S; Moura C; Abecasis N
    Dermatol Ther; 2020 Nov; 33(6):e14093. PubMed ID: 32720460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
    Hata H; Abe R; Suto A; Homma E; Fujita Y; Aoyagi S; Shimizu H
    Br J Dermatol; 2015 Mar; 172(3):769-73. PubMed ID: 25066310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin.
    Fine JD; Johnson LB; Weiner M; Stein A; Suchindran C
    J Am Acad Dermatol; 2004 Apr; 50(4):563-71. PubMed ID: 15034505
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.